Related Experiment Videos
Surgical therapy for gestational trophoblastic disease
1Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710.
The Journal of Reproductive Medicine
|March 1, 1994
Summary
Gestational trophoblastic disease (GTD) management combines human chorionic gonadotropin monitoring and chemotherapy. Surgery, including dilation and curettage or hysterectomy, remains crucial for hydatidiform mole and selected malignant GTD cases.
Area of Science:
- Gynecology
- Oncology
- Reproductive Endocrinology
Background:
- Gestational trophoblastic disease (GTD) requires precise monitoring and tailored treatment.
- Current therapies rely on human chorionic gonadotropin (hCG) assays and risk-factor-based chemotherapy.
Purpose of the Study:
- To review the established and evolving roles of surgical interventions in managing GTD.
- To highlight the integration of surgical procedures with systemic therapies for GTD.
Main Methods:
- Review of current therapeutic strategies for GTD.
- Analysis of the indications for surgical procedures in GTD management.
- Evaluation of the role of surgery in primary and adjunctive therapy.
Main Results:
- Sensitive hCG assays and risk-stratified chemotherapy are standard for GTD.
- Surgical procedures like suction dilation and curettage and hysterectomy are primary treatments for hydatidiform mole.
- Hysterectomy serves as an adjunct for malignant GTD, and thoracotomy may manage drug-resistant cases.
Conclusions:
- Surgical management remains integral to GTD treatment protocols.
- The judicious use of surgery complements chemotherapy in achieving optimal outcomes for GTD patients.
- Extirpative procedures are vital for refractory or localized GTD.